A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Bristol-Myers Squibb
Bristol-Myers Squibb
Turning Point Therapeutics, Inc.
Bristol-Myers Squibb
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc.